pT3-EF1a-NICD1 Citations (7)

Originally described in: Cholangiocarcinomas can originate from hepatocytes in mice.
Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, Gores GJ, Dombrowski F, Evert M, Chen X, Willenbring H J Clin Invest. 2012 Aug 1;122(8):2911-5. doi: 10.1172/JCI63212. Epub 2012 Jul 17. PubMed Journal

---

Articles Citing pT3-EF1a-NICD1

Articles
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, Chin L, Filliol A, Wen W, Song X, Decker A, Worley J, Caviglia JM, Yu L, Yin D, Saito Y, Savage T, Wells RG, Mack M, Zender L, Arpaia N, Remotti HE, Rabadan R, Sims P, Leblond AL, Weber A, Riener MO, Stockwell BR, Gaublomme J, Llovet JM, Kalluri R, Michalopoulos GK, Seki E, Sia D, Chen X, Califano A, Schwabe RF. Cancer Cell. 2021 Jun 14;39(6):866-882.e11. doi: 10.1016/j.ccell.2021.03.012. Epub 2021 Apr 29. PubMed
Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing-Assisted Multiomics Analysis. Bao X, Li Q, Chen J, Chen D, Ye C, Dai X, Wang Y, Li X, Rong X, Cheng F, Jiang M, Zhu Z, Ding Y, Sun R, Liu C, Huang L, Jin Y, Li B, Lu J, Wu W, Guo Y, Fu W, Langley SR, Tano V, Fang W, Guo T, Sheng J, Zhao P, Ruan J. Cancer Immunol Res. 2022 Jul 1;10(7):811-828. doi: 10.1158/2326-6066.CIR-21-1101. PubMed
DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti-DKK1 therapeutic DKN-01. Jarman EJ, Horcas-Lopez M, Waddell SH, MacMaster S, Gournopanos K, Soong DYH, Musialik KI, Tsokkou P, Ng ME, Cambridge WA, Wilson DH, Kagey MH, Newman W, Pollard JW, Boulter L. Liver Int. 2023 Jan;43(1):208-220. doi: 10.1111/liv.15383. Epub 2022 Sep 15. PubMed
Mobilization and activation of tumor-infiltrating dendritic cells inhibits lymph node metastasis in intrahepatic cholangiocarcinoma. Sun BY, Wang ZT, Chen KZ, Song Y, Wu JF, Zhang D, Sun GQ, Zhou J, Fan J, Hu B, Yi Y, Qiu SJ. Cell Death Discov. 2024 Jun 26;10(1):304. doi: 10.1038/s41420-024-02079-z. PubMed
Lymphotoxin beta-activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma. Xu K, Kessler A, Nichetti F, Hoffmeister-Wittmann P, Scherr AL, Nader L, Kelmendi E, Schmitt N, Schwab M, Garcia-Beccaria M, Sobol B, Nieto OA, Isele H, Gartner U, Vaquero-Siguero N, Volk J, Korell F, Mock A, Heide D, Ramadori P, Lenoir B, Albrecht T, Hullein J, Jager D, Frohling S, Springfeld C, Jackstadt R, Heikenwalder M, Dill MT, Roessler S, Goeppert B, Kohler BC. Liver Int. 2024 Nov;44(11):2950-2963. doi: 10.1111/liv.16069. Epub 2024 Aug 20. PubMed
NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma. Lindblad KE, Donne R, Liebling I, Barcena-Varela M, Lozano A, Ruiz de Galarreta M, Dhainaut M, Param NJ, Giotti B, Cappuyns S, Kodama T, Wang Y, Kamphorst AO, Tsankov AM, Lujambio A. Cancer Discov. 2025 Mar 3;15(3):495-510. doi: 10.1158/2159-8290.CD-24-1215. PubMed
Simvastatin overcomes the pPCK1-pLDHA-SPRINGlac axis-mediated ferroptosis and chemo-immunotherapy resistance in AKT-hyperactivated intrahepatic cholangiocarcinoma. Zhu J, Xiong Y, Zhang Y, Liang H, Cheng K, Lu Y, Cai G, Wu Y, Fan Y, Chen X, Zhu H, Ding Z, Zhang W. Cancer Commun (Lond). 2025 Aug;45(8):1038-1071. doi: 10.1002/cac2.70036. Epub 2025 May 29. PubMed

If you have published an article using this material, please email us at to have your article added to this page.